Synthesis and biological activity of isoprenoid bisphosphonates

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 12, 2006, Pages 4130-4136

  Shull, Larry W ^a   Wiemer, Andrew J ^c   Hohl, Raymond J ^b,c   Wiemer, David F ^a,b  

^a E11 SSH   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Bisphosphonate; Isoprenoid metabolism; Post translational processing

Indexed keywords

2,6,12,16 TETRAMETHYL 2,6,11,15 HEPTADECENYL 9,9 BISPHOSPHONIC ACID; 2,6,12,16,20 PENTAMETHYL 2,6,11,15,19 HENICOSAPENTAENYL 9,9 BISPHOSPHONIC ACID; 2,8 DIMETHYL 2,7 NONADIENYL 5,5 BISPHOSPHONIC ACID; 2,8,12 TRIMETHYL 2,7,11 TRIDECATRIENYL 5,5 BISPHOSPHONIC ACID; 2,8,12,16 TETRAMETHYL 2,7,11,15 HEPTADECENYL 5,5 BISPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GUANOSINE TRIPHOSPHATASE; MEVINOLIN; RAP 1A PROTEIN; RAP1 PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE RAS; PROTEIN PROCESSING;

CELL LINE; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; PROTEIN ISOPRENYLATION; RAP1 GTP-BINDING PROTEINS; RAS PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; TUMOR CELLS, CULTURED;

EID: 33646204998     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.02.010     Document Type: Article

References (20)

1. Fleisch H. Eur. Spine J. 12 Suppl 2 (2003) S142-S146
2. Licata A.A. Ann. Pharmacother. 39 (2005) 668-677
3. Swanson K.M., and Hohl R.J. Curr. Cancer Drug Targets 6 (2006) 15-37
4. Reszka A.A., and Rodan G.A. Curr. Osteoporos. Rep. 1 (2003) 45-52
5. Shull L.W., and Wiemer D.F. J. Organomet. Chem. 690 (2005) 2521-2530
6. Presented in part at the 41st Annual Meeting of the American Society for Clinical Oncology Orlando, FL, May 13, 2005. Abstract 6586.
7. For a summary of methods for bisphosphonate synthesis, cf. Du Y., Jung K.Y., and Wiemer D.F. Tetrahedron Lett. 43 (2002) 8665-8668 and references cited therein. For some specific example with an isoprenoid substituent, see Refs. 9-11
8. Ebetino F.H., Degenhardt C.R., Jamieson L.A., and Burdsall D.C. Heterocycles 30 (1990) 855-862
9. Li C.Z., and Yuan C.Y. Heteroatom Chem. 4 (1993) 517-520
10. Liu X., Zhang X.R., and Blackburn G.M. Chem. Commun. (1997) 87-88
11. Holstein S.A., Cermak D.M., Wiemer D.F., Lewis K., and Hohl R.J. Bioorg. Med. Chem. 6 (1998) 687-694
12. Valentijn A.R.P.M., van den Berg O., van der Marel G.A., Cohen L.H., and van Boom J.H. Tetrahedron 51 (1995) 2099-2108
13. Magnin D.R., Biller S.A., Dickson Jr. J.K., Logan J.V., Lawrence R.M., Chen Y., Sulsky R.B., Ciosek Jr. C.P., Harrity T.W., Jolibois K.G., Kunselman L.K., Rich L.C., and Slusarchyk D.A. J. Med. Chem. 38 (1995) 2596-2605
14. McKenna C.E., Higa M.T., Cheung N.H., and McKenna M.C. Tetrahedron Lett. 18 (1977) 155-158
15. Larson R.A., and Yachnin S. Blood 64 (1984) 257-262
16. Holstein S.A., Wohlford-Lenane C.L., and Hohl R.J. J. Biol. Chem. 277 (2002) 10678-10682
17. Hohl R.J., and Lewis K. J. Biol. Chem. 270 (1995) 17508-17512
18. Holstein S.A., and Hohl R.J. Lipids 39 (2004) 293-309
19. Tong H., Holstein S.A., and Hohl R.J. Anal. Biochem. 336 (2005) 51-59
20. Larson R.A., and Yachnin S. J. Clin. Invest. 72 (1983) 1268-1276